Global Information
회사소개 | 문의 | 위시리스트

신장병 치료제 개발 파이프라인 리뷰(2018년)

Renal Diseases Drug Development Pipeline Review, 2018

리서치사 GlobalData
발행일 2018년 12월 상품 코드 766013
페이지 정보 영문 154 Pages
가격
US $ 3,995 ₩ 4,731,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 9,462,000 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 14,193,000 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신장병 치료제 개발 파이프라인 리뷰(2018년) Renal Diseases Drug Development Pipeline Review, 2018
발행일 : 2018년 12월 페이지 정보 : 영문 154 Pages

신장병(Renal Diseases) 파이프라인 상황에 관한 개요를 제공하고, 개발중인 치료제 및 치료제 개발과 관련된 주요 기업에 관한 종합적인 정보를 제공합니다.

제1장 목차

제2장 서론

  • 신장병 조사 범위
  • 만성 신장병(만성 신부전) : 개요
  • 신장 섬유증 : 개요
  • 다발성낭포신(PKD) : 개요
  • 말기 콩팥병(말기 신장병 또는 ESRD) : 개요

제3장 치료제 개발

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)
  • 말기 콩팥병(말기 신장병 또는 ESRD)

제4장 치료제 평가

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)
  • 말기 콩팥병(말기 신장병 또는 ESRD)

제5장 치료제 개발에 관여하는 기업

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)
  • 말기 콩팥병(말기 신장병 또는 ESRD)

제6장 휴지 프로젝트

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)
  • 말기 콩팥병(말기 신장병 또는 ESRD)

제7장 중지 프로젝트

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)
  • 말기 콩팥병(말기 신장병 또는 ESRD)

제8장 제품 개발 마일스톤

  • 만성 신장병(만성 신부전)
  • 신장 섬유증
  • 다발성낭포신(PKD)

제9장 부록

KSM 19.01.16

List of Tables

  • Table 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
  • Table 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 12
  • Table 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
  • Table 4: Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 15
  • Table 5: Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 18
  • Table 6: Number of Products under Development for Kidney Fibrosis 19
  • Table 7: Number of Products under Development by Companies, Kidney Fibrosis 21
  • Table 8: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 22
  • Table 9: Products under Development by Companies, Kidney Fibrosis 23
  • Table 10: Products under Development by Universities/Institutes, Kidney Fibrosis 25
  • Table 11: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 26
  • Table 12: Number of Products under Development by Companies, Kidney Fibrosis 27
  • Table 13: Number of Products under Development by Universities/Institutes, Kidney Fibrosis 27
  • Table 14: Products under Development by Companies, Kidney Fibrosis 28
  • Table 15: Products under Development by Universities/Institutes, Kidney Fibrosis 29
  • Table 16: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
  • Table 17: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
  • Table 18: Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 32
  • Table 19: Number of Products by Stage and Target, Chronic Kidney Disease (Chronic Renal Failure) 34
  • Table 20: Number of Products by Stage and Mechanism of Action, Chronic Kidney Disease (Chronic Renal Failure) 36
  • Table 21: Number of Products by Stage and Route of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
  • Table 22: Number of Products by Stage and Molecule Type, Chronic Kidney Disease (Chronic Renal Failure) 40
  • Table 23: Number of Products by Stage and Target, Kidney Fibrosis 42
  • Table 24: Number of Products by Stage and Mechanism of Action, Kidney Fibrosis 45
  • Table 25: Number of Products by Stage and Route of Administration, Kidney Fibrosis 46
  • Table 26: Number of Products by Stage and Molecule Type, Kidney Fibrosis 48
  • Table 27: Number of Products by Stage and Target, Polycystic Kidney Disease 50
  • Table 28: Number of Products by Stage and Mechanism of Action, Polycystic Kidney Disease 52
  • Table 29: Number of Products by Stage and Route of Administration, Polycystic Kidney Disease 54
  • Table 30: Number of Products by Stage and Molecule Type, Polycystic Kidney Disease 55
  • Table 31: Number of Products by Stage and Target, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
  • Table 32: Number of Products by Stage and Mechanism of Action, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Table 33: Number of Products by Stage and Route of Administration, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Table 34: Number of Products by Stage and Molecule Type, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 60
  • Table 35: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc 61
  • Table 36: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp 61
  • Table 37: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH 62
  • Table 38: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc 62
  • Table 39: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Astellas Pharma Inc 63
  • Table 40: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc 64
  • Table 41: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG 64
  • Table 42: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim GmbH 65
  • Table 43: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd 65
  • Table 44: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd 66
  • Table 45: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc 66
  • Table 46: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc 67
  • Table 47: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Bioscience Pty Ltd 67
  • Table 48: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp 68
  • Table 49: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec AG 69
  • Table 50: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd 69
  • Table 51: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd 70
  • Table 52: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc 70
  • Table 53: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Nash Pharmaceuticals Inc 71
  • Table 54: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG 71
  • Table 55: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc 72
  • Table 56: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC 72

List of Figures

  • Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) 10
  • Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure) 11
  • Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure) 14
  • Figure 4: Number of Products under Development for Kidney Fibrosis 19
  • Figure 5: Number of Products under Development by Companies, Kidney Fibrosis 20
  • Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis 25
  • Figure 7: Number of Products under Development by Companies, Kidney Fibrosis 26
  • Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30
  • Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 31
  • Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
  • Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure) 33
  • Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
  • Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure) 35
  • Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 37
  • Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure) 38
  • Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
  • Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure) 39
  • Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis 40
  • Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis 41
  • Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis 43
  • Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis 44
  • Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis 46
  • Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis 47
  • Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis 47
  • Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease 48
  • Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease 49
  • Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
  • Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease 51
  • Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease 53
  • Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease 53
  • Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease 54
  • Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease 55
  • Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
  • Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56
  • Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 57
  • Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 58
  • Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59
  • Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 59

Abstract

Summary

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.

Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.

This report "Renal Diseases Drug Development Pipeline Review, 2018"provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 9

  • 2.1 Renal Diseases Report Coverage 9
  • 2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview 9
  • 2.3 Kidney Fibrosis - Overview 9
  • 2.4 Polycystic Kidney Disease - Overview 9
  • 2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 9

3 Therapeutics Development 10

  • 3.1 Chronic Kidney Disease (Chronic Renal Failure) 10
  • 3.2 Kidney Fibrosis 19
  • 3.3 Polycystic Kidney Disease 25
  • 3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 30

4 Therapeutics Assessment 33

  • 4.1 Chronic Kidney Disease (Chronic Renal Failure) 33
  • 4.2 Kidney Fibrosis 40
  • 4.3 Polycystic Kidney Disease 48
  • 4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 56

5 Companies Involved in Therapeutics Development 61

  • 5.1 Chronic Kidney Disease (Chronic Renal Failure) 61
  • 5.2 Kidney Fibrosis 80
  • 5.3 Polycystic Kidney Disease 93
  • 5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 99

6 Dormant Projects 102

  • 6.1 Chronic Kidney Disease (Chronic Renal Failure) 102
  • 6.2 Kidney Fibrosis 106
  • 6.3 Polycystic Kidney Disease 107
  • 6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 109

7 Discontinued Products 110

  • 7.1 Chronic Kidney Disease (Chronic Renal Failure) 110
  • 7.2 Kidney Fibrosis 111
  • 7.3 Polycystic Kidney Disease 111
  • 7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) 111

8 Product Development Milestones 112

  • 8.1 Chronic Kidney Disease (Chronic Renal Failure) 112
  • 8.2 Kidney Fibrosis 127
  • 8.3 Polycystic Kidney Disease 139

9 Appendix 153

  • 9.1 Methodology 153
  • 9.2 Coverage 153
  • 9.3 Secondary Research 153
  • 9.4 Primary Research 153
  • 9.5 Expert Panel Validation 153
  • 9.6 Contact Us 153
  • 9.7 Disclaimer 154
Back to Top
전화 문의
F A Q